# Safety, Compliance and Pharmacokinetics of Estetrol Monohydrate/Drospirenone 15/3 mg in Post-menarchal Female Adolescents

> **NCT04792385** · PHASE3 · COMPLETED · sponsor: **Estetra** · enrollment: 145 (actual)

## Conditions studied

- Safety

## Interventions

- **DRUG:** E4/DRSP 15/3 mg combined tablet

## Key facts

- **NCT ID:** NCT04792385
- **Lead sponsor:** Estetra
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-28
- **Primary completion:** 2023-11-24
- **Final completion:** 2023-11-24
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2023-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04792385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04792385, "Safety, Compliance and Pharmacokinetics of Estetrol Monohydrate/Drospirenone 15/3 mg in Post-menarchal Female Adolescents". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04792385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*